Skip to main content

Table 3 Analysis of global inconsistency and heterogeneity

From: Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials

Type

Global inconsistency

Global heterogeneity

Clinical outcome

 
  

I2(%)

I2.pair(%)

I2.cons(%)

 

uGAG

0

79.60122

57.99318

 

CSF GAG

0

2.668657

0

II

6MWT

6

36.38444

0

 

FVC

0

0

0

 

Liver V

11

98.43523

98.27598

 III

uGAG

0

100

0

 

DQ

0

0

0

 

6MWT

0

2.986462

0

IV

3MSCT

0

28.66967

0

 

uKS

20

99.99383

99.99137

  1. 3MSCT: 3-min stair climb test; 6MWT: 6-min walking test; CSF GAG: cerebrospinal fluid glycosaminoglycan; DQ: developmental quotient; FVC: forced vital capacity; uKS: urine keratan sulfate; uGAG: urinary glycosaminoglycan; Liver V: liver volumes